8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 7, 2015

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23143	13-3379479
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York		10591
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code (914) 789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced today that its partner, FUJIFILM RI Pharma Co. Ltd. (Fuji), has dosed the first patient in its early Phase 2 trial of 1404 in Japan in newly-diagnosed prostate cancer patients with lymph node and/or bone metastases or at high risk for metastatic disease. 1404 is a targeted small molecule designed to visualize prostate cancer by targeting prostate specific membrane antigen (PSMA).

A copy of Progenics' press release is included in this Report as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1   Press Release dated April 7, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.
By:	/s/ ANGELO W. LOVALLO, JR.
	Angelo W. Lovallo, Jr.
	Vice President - Finance & Treasurer
	(Principal Financial and Accounting Officer)

Date: April 7, 2015

EX-99.1

Exhibit 99.1

  Progenics Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591 Fax: (914) 789-2817 (914) 789-2800 www.progenics.com

Contact:   Melissa Downs Investor Relations (914) 789-2801 mdowns@progenics.com

PROGENICS ANNOUNCES THE INITIATION OF FUJI'S

PHASE 2 TRIAL FOR 1404 IN JAPAN

TARRYTOWN, NY, April 7, 2015 – Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its partner, FUJIFILM RI Pharma Co. Ltd. (Fuji), has dosed the first patient in its early Phase 2 trial of 1404 in Japan in newly-diagnosed prostate cancer patients with lymph node and/or bone metastases or at high risk for metastatic disease. 1404 is a targeted small molecule designed to visualize prostate cancer by targeting prostate specific membrane antigen (PSMA).

"1404 holds tremendous promise as the most advanced PSMA-targeted imaging agent in development today, and the initiation of this trial reflects Fuji's commitment to 1404 following the impressive data from our own Phase 2 study," stated Mark Baker, CEO of Progenics. "We have demonstrated that 1404 can provide diagnostic information for both primary and metastatic prostate cancer in a single scan, and we look forward to seeing the Japanese development program progress in parallel with our own plans in the United States."

The early Phase 2 trial in Japan is a multi-center, open-label study evaluating the uptake of 1404 within the prostate gland, pelvic lymph node and/or bone metastases as well as safety in men with high risk for metastatic prostate cancer, using both whole-body planar and SPECT/CT imaging modalities.

About 1404, an Imaging Compound Targeting Prostate Specific Membrane Antigen

1404 is a developmental stage radiopharmaceutical imaging agent designed to highlight the expression of distinct proteins by diseased cells. The image created provides the opportunity to visualize cancer, potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.

About Prostate Cancer

Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in six will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that approximately 240,000 new cases of prostate cancer will be diagnosed and about 30,000 men will die of the disease this year, and that approximately two million men in the U.S. currently count themselves among prostate cancer survivors.

Page 2

Progenics Announces the Initiation of Fuji's Phase 2 Trial of 1404 in Japan

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra^™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics' first commercial product, Relistor^® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. For additional information, please visit www.progenics.com.

This press release may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other development activities; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; the sales of products by our partners and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and does not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. For more information, please visit www.progenics.com. Please follow us on LinkedIn^®.

Information on or accessed through our website or social media sites is not included in the company's SEC filings.

(PGNX-F)

Editor's Note:

For more information, please visit www.progenics.com.

For more information about Relistor, please visit www.relistor.com.